carotid News
-
New study finds that carotid Doppler ultrasonography correlates with stroke volume in a human model of hypovolemia and resuscitation
An analysis of 48,570 cardiac cycles revealed that monitoring stroke volume change via carotid Doppler might support the diagnosis and management of evolving hypovolemia Flosonics Medical recently announced a study published in the British Journal of Anaesthesia in which Dr. Jon-Emile S. Kenny and colleagues evaluated the correlation between carotid Doppler ultrasonography and stroke volume ...
-
InspireMD Commences Trading on Nasdaq-CM
InspireMD, Inc. (Nasdaq-CM: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by Carotid Artery Disease (CAD), today announced that the Company’s shares will commence trading on The Nasdaq Capital Market (“Nasdaq-CM”), today, May 21, 2021, under the symbol NSPR. InspireMD CEO Marvin Slosman said, “The trading of our ...
-
Regional and peripheral arterial stiffness measured by pOpmetre(®) in patients with Cvx risk factor, link with carotid plaques
Regional and peripheral arterial stiffness measured by pOpmetre(®) in patients with Cvx risk factor, link with carotid plaques. M Hallab, M Collette, C Terrier-Barbeau, M Legrand, P H Ducluzeau, G Berrut, G Lefthériotis. ANCAAN62 (2013) 189–192 http://dx.doi.org/10.1016/j.ancard.2013.04.001 Chez 77 patients avec comme pathologie un syndrome metabolique. Les 25 patients avec ...
By Axelife SAS
-
InspireMD Receives Reimbursement Approval for CGuard™ Embolic Prevention System from the French National Authority for Health
InspireMD, Inc. (Nasdaq: NSPR), a global developer of the CGuard™ Embolic Prevention Stent System (EPS) device for the treatment of Carotid Artery Disease (CAD) and stroke prevention, today announced that its CGuard EPS stent system has received a positive opinion from the National Commission for the Evaluation of Medical Devices and Health Technologies (CNEDIMTS) of the French National ...
-
InspireMD to Present at the LD Micro Virtual Invitational Conference on June 9, 2021
InspireMD, Inc. (Nasdaq-CM: NSPR) developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by Carotid Artery Disease (CAD), announced today that Chief Executive Officer Marvin Slosman will present a corporate overview at the three-day LD Micro Virtual Invitational Conference being held on June 8 – 10, 2021. Mr. Slosman will deliver his corporate ...
-
InspireMD to Participate at the Investor Summit Conference and Present to Investors on May 17, 2021
InspireMD, Inc. (NYSE American: NSPR) developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of Carotid Artery Disease (CAD), announced today that management will participate at the Investor Summit Conference on May 17, 2021. Chief Executive Officer Marvin Slosman will deliver his corporate presentation at 11:00am ET on May 17, 2021. ...
-
Study Published in JAMA Finds Hospital Availability of TCAR Associated with an Improvement in Overall Outcomes for Carotid Revascularization
Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today announced positive results from a comparative-effectiveness study have been published in JAMA Network Open. The study found the availability of TCAR at a hospital was associated with a significant decrease in the likelihood of major adverse cardiovascular events (MACE), a ...
-
InspireMD to Report Third Quarter 2021 Financial Results on November 9, 2021 and Provide Corporate Business Update -Earnings Conference Call to be held Tuesday, November 9, 2021, at 8:30 a.m. ET
InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) device for the treatment of Carotid Artery Disease (CAD) and stroke prevention, today announces it will report third quarter 2021 financial results on Tuesday, November 9, 2021, before the market opens. Management will host a conference call aand webcast with the investment community at 8:30 am ...
-
First Ever Standard Surgical Risk Patient TCAR Data to be Presented at the Society for Vascular Surgery 2021 Vascular Annual Meeting
Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today announced that key data regarding standard risk patients undergoing treatment for atherosclerotic carotid disease, including patients undergoing carotid endarterectomy (CEA) and transcarotid artery revascularization (TCAR), will be presented at the upcoming Society for ...
-
InspireMD Enrolls and Treats First Patients at Ballad Health System in U.S. Registration C-Guardian Clinical Trial of CGuard EPS
InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) device for the treatment of Carotid Artery Disease (CAD) and stroke prevention, today announces the initiation of enrollment and successful completion of the first cases of the Company’s U.S. registration C-Guardian trial of CGuard EPS. The first patients, who were under the care of ...
-
InspireMD Announces Publication of 12-Month Results of CGuard™ EPS SIBERIA Trial in Journals of the American College of Cardiology: Cardiovascular Interventions
InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of Carotid Artery Disease (CAD), today announced that results from the investigator-initiated SIBERIA randomized clinical trial of CGuard EPS, that evaluated the peri-procedural and 30-day silent brain infarcts associated with the use of its ...
-
Sonia Madigan of the Market Herald interviews CEO Wayne Paterson on the progress of Anteris Technologies
Anteris Technologies (AVR) pauses trading as it plans for an upcoming capital raise On Thursday, the company entered a trading halt, pausing shares until Monday, August 2 It is unknown how much the company is planning to raise or where the funds will be spent On the market, Anteris last traded at $8.59 per share Anteris Technologies (AVR) has paused trading as it plans for an upcoming ...
-
Revacept protects during carotid artery surgery
Good news from vascular medicine: the innovative drug Revacept can protect people with narrowed carotid arteries from both further strokes and dangerous bleeding. Thanks to this completely new dual efficacy, Revacept is ideal for preventing complications after stroke prevention surgery on narrowed carotid arteries. This is the result of an international study conducted according to the highest ...
-
Silicon Valley-Based Silk Road Medical Announces Expansion to MSP Region
Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, recently announced the opening of a new office in Plymouth, Minnesota, to accommodate growing demand for TransCarotid Artery Revascularization (TCAR) and to access the local talent pool of aspiring and experienced med tech professionals. “We continue to invest in our ...
-
Silk Road Medical Announces FDA Approval of Expanded Indications for the ENROUTE Transcarotid Stent System
Silk Road Medical, Inc.?(Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today announced that that the U.S. Food and Drug Administration (FDA) approved expanded indications for the ENROUTE stent to include patients at standard risk for adverse events from carotid endarterectomy (CEA). Previously, the stent was approved for use only in patients with ...
-
CVRx Launches a new Barostim Programmer
MINNEAPOLIS, July 12, 2022 - CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), developer of the world's first FDA-approved neuromodulation device to treat the symptoms of heart failure, has launched its new Barostim Programmer, which was approved by the U.S. Food and Drug Administration (FDA) earlier this year. The second-generation programmer has a modernized design, operates on an upgraded cellular network ...
By CVRx
-
Silk Road Medical Strengthens Leadership Team
Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today announced that it is strengthening its leadership team with two appointments. William Whealon, Ph.D. has joined the company as Executive Vice President of Research and Development, effective immediately. Silk Road Medical has also named Lucas Buchanan, the company’s ...
-
Robocath successfully performs first carotid stenting in France with R-One robot at Rennes University Hospital
Robocath, a company that designs, develops and commercializes innovative robotic platforms for the treatment of vascular diseases, announces today its successful first robotic carotid stenting at Rennes University Hospital. This breakthrough in the neurovascular field was performed on November 16, using Robocath’s R-One robot, operated by Dr. François Eugène and his team. The ...
By Robocath
-
Silk Road Medical Names Rick Anderson to Board of Directors
Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today announced that medical device industry veteran Rick Anderson has joined its board of directors. Anderson brings over 30 years of senior executive leadership experience in the medical device industry. He is the Chairman and Managing Director of Revival Healthcare Capital, a ...
-
Enalare Therapeutics Receives a National Institutes of Health (NIH) Grant Award
Enalare Therapeutics Inc., a biopharmaceutical company dedicated to developing novel therapies for patients suffering from life-threatening critical care conditions, announced today that it has been awarded a grant from the National Institute on Drug Abuse (NIDA), part of the National Institutes of Health (NIH). Funding from the grant will be used to further the development of ENA001, Enalare's ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you